SYSTEMS AND METHODS FOR PREVENTING, MITIGATING, AND/OR TREATING DEMENTIA

    公开(公告)号:US20190105509A1

    公开(公告)日:2019-04-11

    申请号:US16135938

    申请日:2018-09-19

    IPC分类号: A61N5/06

    摘要: Devices, systems, and methods for a treating dementia or Alzheimer's disease in a subject in need thereof. In one example, combined auditory and visual stimuli having a frequency of about 20 Hz to about 60 Hz, and more specifically about 40 Hz, are non-invasively delivered to the subject to induce synchronized gamma oscillations in at least one brain region of the subject. In particular, pursuant to various treatment and exposure protocols, combined auditory and visual stimulation (as opposed to auditory or visual stimulation alone) promotes a microglia response in the medial prefrontal cortex (mPFC). More generally, combined auditory and visual stimulation induces an extended microglia clustering response in the auditory cortex, the visual cortex, and the mPFC.

    Transgenic mice expressing inducible human p25
    6.
    发明授权
    Transgenic mice expressing inducible human p25 失效
    表达诱导型人p25的转基因小鼠

    公开(公告)号:US07250551B2

    公开(公告)日:2007-07-31

    申请号:US10625986

    申请日:2003-07-24

    摘要: Disclosed are improved methods of treating individuals with Alzheimer's disease (AD) as well as methods to diagnose AD in an individual. Also included are compounds and methods of identifying compounds to treat AD. The present invention also discloses methods for decreasing the phosphorylation of amyloid precursor protein (APP), including inhibiting phosphorylation of amino acid residue tyrosine 668 of APP and for reducing cleavage of APP. The present invention further discloses transgenic (Tg), non-human animals and cells expressing a p25 transgene that are models of neurodegenerative diseases. Embodiments of the present invention are directed to methods wherein the Tg animals and Tg cells of the invention are used to screen for modulators of neurodegenerative disorders. The Tg animals and cells of the present invention are useful for elucidating the mechanisms of neurodegenerative disorders.

    摘要翻译: 公开了治疗患有阿尔茨海默病(AD)的个体的改进方法以及在个体中诊断AD的方法。 还包括鉴定化合物以治疗AD的化合物和方法。 本发明还公开了降低淀粉样蛋白前体蛋白(APP)的磷酸化的方法,包括抑制APP的氨基酸残基酪氨酸668的磷酸化和减少APP的切割。 本发明还公开了转基因(Tg)非人动物和表达作为神经变性疾病模型的p25转基因的细胞。 本发明的实施方案涉及其中本发明的Tg动物和Tg细胞用于筛选神经变性疾病的调节剂的方法。 本发明的Tg动物和细胞可用于阐明神经变性疾病的机制。

    Solid-phase capture-release-tag methods for phosphoproteomic analyses
    7.
    发明申请
    Solid-phase capture-release-tag methods for phosphoproteomic analyses 审中-公开
    用于磷酸化蛋白质组学分析的固相捕获释放标签方法

    公开(公告)号:US20050261475A1

    公开(公告)日:2005-11-24

    申请号:US11058735

    申请日:2005-02-14

    IPC分类号: C07K1/02 C07K1/13 C07K14/47

    CPC分类号: C07K1/13

    摘要: One aspect of the present invention relates to a method of labeling a peptide or protein comprising a phosphorylated amino acid comprising: a) removing from the peptide or protein the phosphate group via a β-elimination to form a double bond conjugated to a C═O group; b) reacting the double bond from step a) with a nucleophile comprising a tag on a solid support; and c) removing the solid support from the product of step b) forming the labeled peptide or protein. A second aspect of the invention relates to a solid support comprising a linker and tag between the solid support and a nucleophile, wherein the tag comprises a label.

    摘要翻译: 本发明的一个方面涉及标记包含磷酸化氨基酸的肽或蛋白质的方法,包括:a)通过β-消除从肽或蛋白质去除磷酸基团以形成与C-O基团缀合的双键; b)使来自步骤a)的双键与在固体载体上包含标签的亲核试剂反应; 和c)从步骤b)的产物中除去固体支持物,形成标记的肽或蛋白质。 本发明的第二方面涉及一种固体支持物,其包含固体支持物和亲核试剂之间的接头和标签,其中标签包含标签。